Table A2:
Studies Reviewed in OCT Monitoring Strategies for A-VEGF Treated n-AMD
| Authors | Title | Publication |
|---|---|---|
| Abraham P, Yue H, Wilson L | Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2 | Am J Ophthalmol. 2010 Sep;150(3):315–24 |
| Antoszyk AN, Tuomi L, Chung CY, Singh A. FOCUS Study Group | Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results | Am J Ophthalmol. 2008 May;145(5):862–74 |
| Bandukwala T, Muni RH, Schwartz C, Eng KT, Kertes PJ | Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: A retrospective review | Can J Ophthalmol. 2010;45(6):590–5 |
| Bolz M, Simader C, Ritter M, Ahlers C, Benesch T, Prunte C, et al | Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration | Br J Ophthalmol. 2010;94(2):185–9 |
| Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG | A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration | Ophthalmology. 2009;116(9):1731–9 |
| Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al | Ranibizumab versus verteporfin for neovascular age related macular degeneration | N Engl J Med. 2006 Oct 5;355(14):1432 |
| Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T | Ranibizumab versus verteporfin photodynamic therapy for neovascular age related macular degeneration: Two year results of the ANCHOR study | Ophthalmology. 2009 Jan;116(1):57 |
| Carneiro AM, Mendonca LS, Falcao MS, Fonseca SL, Brandao EM, Falcao-Reis FM | Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting | Clin Ophthalmol. 2012;6(1):1149–57 |
| Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al | Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial | Ophthalmology. 2012 Jul;119(7):1399–41 |
| Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C, et al | Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting | Am J Ophthalmol. 2009 Sep;148(3):409–13 |
| Cohen SY, Oubraham H, Uzzan J, Dubois L, Tadayoni R | Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings | Retina. 2012 Sep;32(8):1480–5 |
| Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK | Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration | Ophthalmology. 2009 Sep;116(9):1740–7 |
| El-Mollayess GM, Mahfoud Z, Schakal AR, Salti HI, Jaafar D, Bashshur ZF | Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study | Am J Ophthalmol. 2012;153(3):481–9 |
| Ernst BJ, Barkmeier AJ, Akduman L | Optical coherence tomography-based intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration | Int Ophthalmol. 2010 Jun;30(3):267–70 |
| Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, et al | An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration | Am J Ophthalmol. 2007 Apr;143(4):566–83 |
| Fung AT, Kumar N, Vance SK, Slakter JS, Klancnik JM, Spaide RS, et al | Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study) | Eye. 2012;26:1181–7 |
| Gerding H, Loukopoulos V, Riese J, Hefner L, Timmermann M | Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome | Graefes Arch Clin Exp Ophthalmol. 2011 May;249(5):653–62 |
| Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, et al | Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study | Arch Ophthalmol. 2006 Nov;124(11):1532–42 |
| Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al | Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration | Ophthalmology. 2012 Dec;119(12):2537–48 |
| Heimes B, Lommatzsch A, Zeimer M, Gutfleisch M, Spital G, Dietzel M, et al | Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme | Graefes Arch Clin Exp Ophthalmol. 2011 May;249(5):639–44 |
| Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, et al | Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN study | Ophthalmology. 2011;118(4):663–71 |
| Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A | Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study | Ophthalmology. 2012 May;119(5):1001–10 |
| Kang S, Roh YJ | One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups | Jpn J Ophthalmol. 2009 Jul;53(4):389–95 |
| Katz G, Giavedoni L, Muni R, Evans T, Pezda M, Wong D, et al | Effectiveness at 1 year of monthly versus variable-dosing intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to age-related macular degeneration | Retina. 2012;32(2):293–8 |
| Krebs I, Vecsei M, V, Bodenstorfer J, Glittenberg C, Ansari SS, Ristl R, et al | Comparison of Ranibizumab monotherapy versus combination of ranibizumab with photodynamic therapy with neovascular age-related macular degeneration | Acta Ophthalmol. 2013 May;91(3):e178–e183 |
| Krebs I, Schmetterer L, Boltz A, Told R, Vecsei-Marlovits V, Egger S, et al | A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. | Br J Ophthalmol. 2013 Mar;97(3):266–71 |
| Kruger FM, Kemp H, Sorensen TL | Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment | Am J Ophthalmol. 2013 Jan;155(1):89–95 |
| Kumar A, Sahni JN, Stangos AN, Campa C, Harding SP | Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined re-treatment strategy | Br J Ophthalmol. 2011;95(4):530–3 |
| Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al | A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study | J Ophthalmol. 2009 Jul;148(1):43–58 |
| Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E, et al | Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results | Ophthalmology. 2012 May;119(5):992–1000 |
| Li X, Hu Y, Sun X, Zhang J, Zhang M, Neovascular Age-Related Macular Degeneration Treatment Trial Using Bevacizumab (NATTB) | Bevacizumab for neovascular age-related macular degeneration in China | Ophthalmology. 2012;119(10):2087–93 |
| Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ | Ranibizumab and bevacizumab for neovascular age-related macular degeneration | N Engl J Med. 2011 May 19;364(20):1897–908 |
| Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al | Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results | Ophthalmology. 2012 Jul;119(7):1388–98 |
| Michalova K, Wickremasinghe SS, Tan TH, Chang A, Harper CA, Downie JA, et al | Ranibizumab treatment for neovascular age-related macular degeneration: from randomized trials to clinical practice | Eye. 2009 Aug;23(8):1633–40 |
| Muether PS, Hoerster R, Hermann MM, Kirchhof B, Fauser S | Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration | Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):453–8 |
| Muniraju R, Ramu J, Sivaprasad S | Three-year visual outcome and Injection frequency of intravitreal ranibizumab therapy for neovascular age-related macular degeneration | Ophthalmologica. 2013 Apr 30;230(1):27–33 |
| Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel P, et al | Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration | Retina. 2011 Jan;31(1):26–30 |
| Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al | Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 | Am J Ophthalmol. 2008 Feb;145(2):239–48 |
| Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE | Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration | Am J Ophthalmol. 2009 May;147(5):831–7 |
| Rudnisky CJ, Liu C, Ng M, Weis E, Tennant MT | Intravitreal bevacizumab alone versus combined verteporfin photodynamic therapy and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: visual acuity after 1 year of follow-up | Retina. 2010 Apr;30(4):548–54 |
| Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, et al | Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study | Ophthalmology. 2011;118(5):831–9 |
| Silva R, Axer-Siegel R, Eldem B, Guymer R, Kirchhof B, Papp A, et al | The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration | Ophthalmology. 2013 Jan;120(1):130–9 |
| Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, et al | HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration | Ophthalmology. 2012 Jun;119(6):1175–83 |
| Soderberg A-C, Algvere PV, Hengstler JC, Soderberg P, Seregard S, Kvanta A | Combination therapy with low-dose transpupillary thermotherapy and intravitreal ranibizumab for neovascular age-related macular degeneration: A 24-month prospective randomised clinical study | Br J Ophthalmol. 2012;96(5):714–8 |
| Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, Daly MK, et al | Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial | Eye. 2010;24(11):1708–15 |
| Williams PD, Callanan D, Solley W, Avery RL, Pieramici DJ, Aaberg T | A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration | Clin Ophthalmol. 2012;6(1):1519–25 |
| Ying G-S, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, et al | Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration | Ophthalmology. 2013;120(1):122–9 |